ELEVANCE HEALTH: LEERINK PARTNERS INCREASES TARGET PRICE TO $364, UP FROM $357
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy ELV?
Source: moomoo
Price Increase Announcement: Lee Rink Partners has raised the target price for a specific stock to $364 from a previous price of $357.
Market Implications: This adjustment in target price may reflect positive expectations for the company's performance or market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 376.420
Low
332.00
Averages
389.07
High
425.00
Current: 376.420
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health Honors Outstanding Medical Practices
- Annual Recognition Program: Elevance Health announces the honoring of 45 distinguished medical practices and health systems, showcasing their excellence within a nationwide network of approximately 7,200 value-based care providers, reflecting the company's commitment to high-quality healthcare services.
- Quality Care Standards: The honorees are selected based on key performance metrics, including preventive care screenings, immunization rates, chronic disease management, and medication adherence, ensuring the delivery of coordinated, high-quality care that enhances patient experiences.
- Role of Care Providers: Dr. Catherine Gaffigan, President of Health Solutions at Elevance Health, emphasizes that primary care providers act as the “quarterbacks” of the healthcare system, improving quality and outcomes through personalized care while demonstrating a strong commitment to meeting the unique needs of patients and their communities.
- Broad Impact: Elevance Health serves approximately 104 million consumers through a diverse portfolio of medical, pharmacy, behavioral health, and complex care solutions, further solidifying its position as a trusted health partner in the industry.
See More
Latest Wall Street Rating Updates
- Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
- Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
- CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
- Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
ELEVANCE HEALTH: LEERINK PARTNERS INCREASES TARGET PRICE TO $364, UP FROM $357
Price Increase Announcement: Lee Rink Partners has raised the target price for a specific stock to $364 from a previous price of $357.
Market Implications: This adjustment in target price may reflect positive expectations for the company's performance or market conditions.
See More
Elevance Health Faces Investigation Over CMS Sanctions
- CMS Sanction Notification: On March 2, 2026, Elevance Health disclosed that the Centers for Medicare & Medicaid Services (CMS) intends to impose intermediate sanctions due to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements, which could significantly disrupt its business operations.
- Stock Price Decline: Following the announcement of the sanctions, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, marking an 8.1% decline, indicating market concerns regarding the company's compliance issues.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Elevance investors to determine potential violations of federal securities laws, although no lawsuits have been filed yet, the investigation may lead to future legal actions.
- Investor Rights Protection: Investors who purchased Elevance shares during this period are encouraged to contact Kirby McInerney LLP to discuss their rights, highlighting the firm's commitment to protecting investor interests amidst these developments.
See More
Elevance Health (ELV) Q1 2025 Earnings Transcript
See More
Elevance Health Honors Outstanding Medical Practices
- Annual Recognition Program: Elevance Health announces the honoring of 45 distinguished medical practices and health systems, showcasing their excellence within a nationwide network of approximately 7,200 value-based care providers, reflecting the company's commitment to high-quality healthcare services.
- Quality Care Standards: The honorees are selected based on key performance metrics, including preventive care screenings, immunization rates, chronic disease management, and medication adherence, ensuring the delivery of coordinated, high-quality care that enhances patient experiences.
- Role of Care Providers: Dr. Catherine Gaffigan, President of Health Solutions at Elevance Health, emphasizes that primary care providers act as the “quarterbacks” of the healthcare system, improving quality and outcomes through personalized care while demonstrating a strong commitment to meeting the unique needs of patients and their communities.
- Broad Impact: Elevance Health serves approximately 104 million consumers through a diverse portfolio of medical, pharmacy, behavioral health, and complex care solutions, further solidifying its position as a trusted health partner in the industry.
See More
Latest Wall Street Rating Updates
- Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
- Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
- CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
- Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
ELEVANCE HEALTH: LEERINK PARTNERS INCREASES TARGET PRICE TO $364, UP FROM $357
Price Increase Announcement: Lee Rink Partners has raised the target price for a specific stock to $364 from a previous price of $357.
Market Implications: This adjustment in target price may reflect positive expectations for the company's performance or market conditions.
See More
Elevance Health Faces Investigation Over CMS Sanctions
- CMS Sanction Notification: On March 2, 2026, Elevance Health disclosed that the Centers for Medicare & Medicaid Services (CMS) intends to impose intermediate sanctions due to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements, which could significantly disrupt its business operations.
- Stock Price Decline: Following the announcement of the sanctions, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, marking an 8.1% decline, indicating market concerns regarding the company's compliance issues.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Elevance investors to determine potential violations of federal securities laws, although no lawsuits have been filed yet, the investigation may lead to future legal actions.
- Investor Rights Protection: Investors who purchased Elevance shares during this period are encouraged to contact Kirby McInerney LLP to discuss their rights, highlighting the firm's commitment to protecting investor interests amidst these developments.
See More
Elevance Health (ELV) Q1 2025 Earnings Transcript
See More
